Leonie M. Middelink, MSc (she/her/hers)

Middelinc
Utrecht, Netherlands

Independent Drug Development Executive

Presentation(s):

• L08: Early Clinical Development of CIT-013, a First in Class NETosis Inhibitor, in a Randomized Phase I Dose Escalation Study in Healthy Volunteers Demonstrating Potent Inhibition of LPS Induced Neutrophil Extracellular Trap Formation

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure information not submitted.